Articles

  • 2 weeks ago | ajmc.com | Ajai Chari |Kyle Munz

    In recent years, dramatic clinical trial results in multiple myeloma have dominated plenary sessions and news conferences at major cancer meetings.

  • 1 month ago | ajmc.com | Kyle Munz |Ajai Chari

    While much attention has been given to the merits and potential of triple and quadruple therapy in multiple myeloma, Ajai Chari, MD, University of California, San Francisco, emphasized how it is not just the number of agents that matters in successful treatments, but how they are used. Dosing intensity, frequency, and real-world feasibility often carry more weight than the theoretical power of a multi-drug regimen.

  • 1 month ago | ajmc.com | Kyle Munz |Ajai Chari

    For many patients with multiple myeloma, how a regimen is dosed may matter more than how many agents are included, according to Ajai Chari, MD, of the University of California San Francisco. As the field explores novel triplet and quadruplet combinations, Chari emphasized the need for more personalized treatment approaches—not just to advance research, but to improve outcomes for older, frail, and high-risk populations.

  • 2 months ago | ajmc.com | Kyle Munz |Ajai Chari

    The future of multiple myeloma treatment is bright, but it hinges on overcoming barriers to access and affordability, argued Ajai Chari, MD, University of California San Francisco, in an interview with The American Journal of Managed Care®. As he previously discussed, chimeric antigen receptor (CAR) T-cell and bispecific therapies have fundamentally altered patient outcomes and quality of life for patients with multiple myeloma (MM).

  • 2 months ago | ajmc.com | Kyle Munz |Ajai Chari

    Previously, Ajai Chari, MD, University of California San Francisco (UCSF), spoke to the operational challenges of integrating chimeric antigen receptor T-cell (CAR T) and bispecific therapies into clinical practice. Notably, he emphasized the need to educate providers to manage potential adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →